Skip to content
Screener

Eikon Therapeutics, Inc. EIKN Cash & Equivalents

Cash & Equivalents at other companies

Gilead Sciences logo
Gilead SciencesGILD
$3.18B-38.2%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$157.52M+21.2%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$161.66M-25.3%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$192.11M+98.7%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Erasca, Inc. logo
Erasca, Inc.ERAS
$47.26M-33.0%

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$498.62M-36.3%
Enterprise value$592.29M—

Returns & leverage

See full
Debt / equity0.5×—
Current ratio11.8×—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216791

FAQ

What is Eikon Therapeutics, Inc.'s cash & equivalents?
Eikon Therapeutics, Inc. (EIKN) reported cash & equivalents of $161.15M in Q1 2026.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Eikon Therapeutics, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude